IL215061A0 - Compounds, compositions and methods of treating cancer and fibrotic diseases - Google Patents
Compounds, compositions and methods of treating cancer and fibrotic diseasesInfo
- Publication number
- IL215061A0 IL215061A0 IL215061A IL21506111A IL215061A0 IL 215061 A0 IL215061 A0 IL 215061A0 IL 215061 A IL215061 A IL 215061A IL 21506111 A IL21506111 A IL 21506111A IL 215061 A0 IL215061 A0 IL 215061A0
- Authority
- IL
- Israel
- Prior art keywords
- compositions
- compounds
- methods
- treating cancer
- fibrotic diseases
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000003176 fibrotic effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16234809P | 2009-03-23 | 2009-03-23 | |
| PCT/US2010/028200 WO2010111198A1 (en) | 2009-03-23 | 2010-03-23 | Compounds compositions and methods of treating cancer and fibrotic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL215061A0 true IL215061A0 (en) | 2011-11-30 |
Family
ID=42288813
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL215061A IL215061A0 (en) | 2009-03-23 | 2011-09-08 | Compounds, compositions and methods of treating cancer and fibrotic diseases |
| IL235026A IL235026A (en) | 2009-03-23 | 2014-10-06 | Anti-endo180 antibody or antigen-binding fragment and the right composition |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL235026A IL235026A (en) | 2009-03-23 | 2014-10-06 | Anti-endo180 antibody or antigen-binding fragment and the right composition |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US8444983B2 (enExample) |
| EP (1) | EP2411413B1 (enExample) |
| JP (2) | JP5830460B2 (enExample) |
| CN (2) | CN104861066B (enExample) |
| CA (1) | CA2753388C (enExample) |
| IL (2) | IL215061A0 (enExample) |
| SG (1) | SG174367A1 (enExample) |
| WO (1) | WO2010111198A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2411413B1 (en) | 2009-03-23 | 2016-05-11 | Quark Pharmaceuticals, Inc. | Compounds compositions and methods of treating cancer and fibrotic diseases |
| JP2015509085A (ja) * | 2012-01-01 | 2015-03-26 | キュービーアイ エンタープライゼズ リミテッドＱｂｉ Ｅｎｔｅｒｐｒｉｓｅｓ Ｌｔｄ． | 治療剤および診断剤の選択的送達のためのｅｎｄｏ１８０を標的とする粒子 |
| WO2014191391A1 (en) * | 2013-05-27 | 2014-12-04 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Targeted modulation of macrophages |
| US9572832B2 (en) * | 2013-08-29 | 2017-02-21 | Holy Stone Healthcare Co., Ltd. | Compound of glycosaminoglycan and its fabrication method as well as application |
| TW202330606A (zh) | 2014-03-21 | 2023-08-01 | 美商艾伯維有限公司 | 抗-egfr抗體及抗體藥物結合物 |
| WO2015179239A1 (en) * | 2014-05-17 | 2015-11-26 | University Of Rochester | Compositions and methods to inhibit estrogen receptor beta for the treatment of renal cell carcinoma |
| SG11201701809UA (en) | 2014-09-08 | 2017-04-27 | Nat Cancer Ct | Cancer cell-specific antibody, anticancer drug and cancer testing method |
| LT3411076T (lt) | 2016-02-05 | 2021-07-26 | Rigshospitalet | Antikūno-vaisto konjugatai, kurių taikinys uparap |
| WO2017214339A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
| CN109963870B (zh) | 2016-06-08 | 2023-07-28 | 艾伯维公司 | 抗b7-h3抗体和抗体药物偶联物 |
| CA3027044A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
| JP2019524651A (ja) | 2016-06-08 | 2019-09-05 | アッヴィ・インコーポレイテッド | 抗ｃｄ９８抗体及び抗体薬物コンジュゲート |
| US11584932B2 (en) | 2016-11-01 | 2023-02-21 | The Research Foundation For The State University Of New York | 5-halouracil-modified microRNAs and their use in the treatment of cancer |
| CN110177544A (zh) | 2016-11-29 | 2019-08-27 | 普尔泰克健康有限公司 | 用于递送治疗剂的外泌体 |
| WO2018112334A1 (en) | 2016-12-16 | 2018-06-21 | Bluefin Biomedicine, Inc. | Anti-cub domain-containing protein 1 (cdcp1) antibodies, antibody drug conjugates, and methods of use thereof |
| EP3612567B1 (en) | 2017-04-19 | 2024-09-11 | Bluefin Biomedicine, Inc. | Anti-vtcn1 antibodies and antibody drug conjugates |
| CN118994394A (zh) | 2017-06-12 | 2024-11-22 | 蓝鳍生物医药公司 | 抗-il1rap抗体和抗体药物缀合物 |
| JP7232453B2 (ja) * | 2017-09-15 | 2023-03-03 | 学校法人杏林学園 | 糖尿病網膜症、白内障及び／又は腎症モデル実験動物 |
| WO2021113761A1 (en) * | 2019-12-05 | 2021-06-10 | Board Of Regents, The University Of Texas System | Exosomes-based therapy for liver fibrosis and other diseases associated with fibrosis |
| WO2021262919A2 (en) | 2020-06-26 | 2021-12-30 | The Research Foundation For The State University Of New York | 5-halouracil-modified micrornas and their use in the treatment of cancer |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| KR20240024816A (ko) | 2021-06-29 | 2024-02-26 | 릭스하스피탈렛 | 우로키나제 유형 플라스미노겐 활성제 수용체 관련 단백질(uparap)을 표적으로 하는 인간화 항체를 포함하는 항체-약물 접합체 |
| EP4642487A1 (en) | 2022-12-28 | 2025-11-05 | Adcendo ApS | Antibody-drug conjugates targeting uparap comprising exatecan derivatives |
| WO2025027529A1 (en) | 2023-07-31 | 2025-02-06 | Advesya | Anti-il-1rap antibody drug conjugates and methods of use thereof |
| TW202530255A (zh) | 2023-12-15 | 2025-08-01 | 法商亞維西亞有限公司 | 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物 |
| WO2025141153A1 (en) * | 2023-12-29 | 2025-07-03 | Oncomatryx Biopharma, S.L. | Endo180 targeted antibody-drug conjugates |
| EP4578463A1 (en) * | 2023-12-29 | 2025-07-02 | Oncomatryx Biopharma, S.L. | Endo-180 targeted antibody-drug conjugates |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL81370A (en) * | 1986-02-07 | 1991-06-30 | Genetic Systems Corp | Pharmaceutical and diagnostic compositions comprising a plurality of human monoclonal antibodies for the treatment of bacterial diseases,methods for the preparation of the compositions and antibodies and kits containing said compositions |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6153737A (en) | 1990-01-11 | 2000-11-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
| US6235886B1 (en) | 1993-09-03 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Methods of synthesis and use |
| US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
| ATE204325T1 (de) | 1993-04-29 | 2001-09-15 | Unilever Nv | Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae |
| US5773268A (en) * | 1994-11-09 | 1998-06-30 | Cedars-Sinai Medical Center | Chromosome 21 gene marker, compositions and methods using same |
| US6117977A (en) | 1996-04-24 | 2000-09-12 | Genentech, Inc. | Type C lectins |
| ZA973051B (en) | 1996-04-24 | 1998-10-12 | Genentech Inc | Type c lectins |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US20050042647A1 (en) | 1996-06-06 | 2005-02-24 | Baker Brenda F. | Phosphorous-linked oligomeric compounds and their use in gene modulation |
| US6251666B1 (en) | 1997-03-31 | 2001-06-26 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid catalysts comprising L-nucleotide analogs |
| US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
| US6077508A (en) | 1998-03-23 | 2000-06-20 | American Diagnostica Inc. | Urokinase plasminogen activator receptor as a target for diagnosis of metastases |
| CA2383592A1 (en) | 1999-03-31 | 2000-10-05 | Curagen Corporation | 2384891 acids including open reading frames encoding polypeptides; orfx |
| ATE350661T1 (de) | 1999-04-13 | 2007-01-15 | Wilex Ag | Diagnostischer und therapeutischer einsatz von antikörpern gegen den urokinase-rezeptor |
| US7829064B2 (en) * | 1999-05-10 | 2010-11-09 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| DK2796553T3 (da) | 2000-03-30 | 2019-09-30 | Whitehead Inst Biomedical Res | Rna-sekvensspecifikke formidlere af rna-interferens |
| CZ302719B6 (cs) | 2000-12-01 | 2011-09-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití |
| ES2607802T3 (es) | 2001-08-14 | 2017-04-04 | Tel Aviv University Future Technology Development L.P. | Partículas lipidadas de glicosaminoglicano y su uso en el suministro de fármacos y genes para diagnóstico y terapia |
| DE10230997A1 (de) | 2001-10-26 | 2003-07-17 | Ribopharma Ag | Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels |
| WO2003035876A1 (de) | 2001-10-26 | 2003-05-01 | Ribopharma Ag | Verwendung einer doppelsträngigen ribonukleinsäure zur behandlung einer infektion mit einem (+)-strang-rna-virus |
| US7795422B2 (en) | 2002-02-20 | 2010-09-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA) |
| DK1527176T4 (en) | 2002-08-05 | 2017-07-03 | Silence Therapeutics Gmbh | ADDITIONAL NEW FORMS OF INTERFERRING RNA MOLECULES |
| US8729036B2 (en) | 2002-08-07 | 2014-05-20 | University Of Massachusetts | Compositions for RNA interference and methods of use thereof |
| EP1560931B1 (en) | 2002-11-14 | 2011-07-27 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| EP1624788A2 (en) * | 2003-05-19 | 2006-02-15 | Quark Biotech, Inc. | Use of endo180 receptor for diagnosis and treatment of disease |
| US7842800B2 (en) | 2004-04-02 | 2010-11-30 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory bacterial and bacterial associated oligonucleotides and uses thereof |
| WO2006017195A1 (en) | 2004-07-13 | 2006-02-16 | Ramot At Tel-Aviv University Ltd. | Lipidated glycoprotein particles and methods of use |
| JP4903146B2 (ja) | 2004-08-16 | 2012-03-28 | イミューン ディズィーズ インスティテュート インコーポレイテッド | Ｒｎａ干渉を送達する方法およびその使用法 |
| JP2008519076A (ja) | 2004-11-02 | 2008-06-05 | テルアビブ ユニバーシティ フューチャー テクノロジー デベロップメント エル．ピー． | 脂質化グリコサミノグリカン粒子中の水不溶性又は水難溶性薬物の処方、並びに診断及び治療のためのこれらの使用 |
| WO2008020435A2 (en) | 2006-08-15 | 2008-02-21 | Quark Pharmaceuticals, Inc | Compositions and methods for treatment of mood disorders |
| JP2010507387A (ja) | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のｓｉＲＮＡおよびその使用方法 |
| WO2008104978A2 (en) | 2007-02-28 | 2008-09-04 | Quark Pharmaceuticals, Inc. | Novel sirna structures |
| US20080311040A1 (en) * | 2007-03-06 | 2008-12-18 | Flagship Ventures | METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA |
| US8614309B2 (en) | 2007-10-03 | 2013-12-24 | Quark Pharmaceuticals, Inc. | Double-stranded RNA directed to CASP2 and methods of use thereof |
| EP2259775B1 (en) * | 2008-02-27 | 2015-07-22 | Ramot at Tel-Aviv University Ltd. | System for delivery of protein in insoluble fibrillar form |
| EP2411413B1 (en) | 2009-03-23 | 2016-05-11 | Quark Pharmaceuticals, Inc. | Compounds compositions and methods of treating cancer and fibrotic diseases |
| AU2010324658A1 (en) | 2009-11-26 | 2012-05-03 | Quark Pharmaceuticals, Inc. | siRNA compounds comprising terminal substitutions |
-
2010
- 2010-03-23 EP EP10722812.4A patent/EP2411413B1/en not_active Not-in-force
- 2010-03-23 CN CN201510009172.XA patent/CN104861066B/zh not_active Expired - Fee Related
- 2010-03-23 US US13/255,214 patent/US8444983B2/en active Active
- 2010-03-23 WO PCT/US2010/028200 patent/WO2010111198A1/en not_active Ceased
- 2010-03-23 JP JP2012502150A patent/JP5830460B2/ja not_active Expired - Fee Related
- 2010-03-23 CN CN201080012287XA patent/CN102378766A/zh active Pending
- 2010-03-23 SG SG2011065935A patent/SG174367A1/en unknown
- 2010-03-23 CA CA2753388A patent/CA2753388C/en not_active Expired - Fee Related
-
2011
- 2011-09-08 IL IL215061A patent/IL215061A0/en active IP Right Grant
-
2013
- 2013-05-02 US US13/886,010 patent/US20140072552A1/en not_active Abandoned
-
2014
- 2014-10-06 IL IL235026A patent/IL235026A/en active IP Right Grant
-
2015
- 2015-07-09 US US14/795,429 patent/US9993567B2/en active Active
- 2015-08-12 JP JP2015159597A patent/JP2016034945A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016034945A (ja) | 2016-03-17 |
| JP2012521217A (ja) | 2012-09-13 |
| CN104861066A (zh) | 2015-08-26 |
| IL235026A (en) | 2016-10-31 |
| US20150359905A1 (en) | 2015-12-17 |
| US9993567B2 (en) | 2018-06-12 |
| CN102378766A (zh) | 2012-03-14 |
| US20120114704A1 (en) | 2012-05-10 |
| WO2010111198A1 (en) | 2010-09-30 |
| JP5830460B2 (ja) | 2015-12-09 |
| CA2753388A1 (en) | 2010-09-30 |
| SG174367A1 (en) | 2011-10-28 |
| US20140072552A1 (en) | 2014-03-13 |
| EP2411413B1 (en) | 2016-05-11 |
| CN104861066B (zh) | 2018-05-08 |
| US8444983B2 (en) | 2013-05-21 |
| EP2411413A1 (en) | 2012-02-01 |
| CA2753388C (en) | 2016-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL215061A0 (en) | Compounds, compositions and methods of treating cancer and fibrotic diseases | |
| IL276362A (en) | Cancer treatment methods | |
| IL218575A0 (en) | Treatment of cancer | |
| IL258794B (en) | Methods and preparations for the diagnosis and treatment of cancer | |
| IL218987A0 (en) | Methods and compositions for treating cancer | |
| IL214255A0 (en) | Methods and compositions for diagnosis and treatment of cancer | |
| EP2435825B8 (en) | Methods of treating diseases | |
| SG10201508495VA (en) | Combination treatment of cancer | |
| EP2461814A4 (en) | PROSTATE CANCER TREATMENT | |
| ZA201304226B (en) | Methods of treating cancer | |
| ZA201106577B (en) | Compounds and compositions for cognition-enhancement,methods of making,and methods of treating | |
| IL214349A0 (en) | Compositions and methods for the treatment of cancer | |
| EP2640390A4 (en) | METHODS OF TREATING CANCER | |
| EP2391211A4 (en) | METHODS AND COMPOSITIONS FOR TREATING BREAST CANCER | |
| IL218230A0 (en) | Method of treating cancer | |
| EP2515652A4 (en) | COMPOSITIONS AND METHODS FOR TREATING VITILIGO | |
| GB0916686D0 (en) | Treatment of cancer | |
| GB0921757D0 (en) | Treatment of cancer | |
| AU2009900764A0 (en) | Treatment of cancer | |
| GB201017354D0 (en) | Treatment of cancer | |
| GB201017356D0 (en) | Combination treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed |